Syneron Medical (ELOS) Receives FDA Approval for Plus
Tweet
Share
E-mailGet Alerts ELOS Hot Sheet
Join SI Premium – FREE
Syneron Medical Ltd. (NASDAQ: ELOS) has received United States Food and Drug Administration (FDA) clearance for elos Plus™, a next generation multi-platform system featuring the Company's proprietary elos technology. The FDA clearance for elos Plus™ follows on the recent international launch in Europe and Asia.
The new elos Plus™ leverages the Company's proprietary elos® technology of optical energy and bi-polar radiofrequency to provide safe and efficacious treatments.
The new elos Plus™ leverages the Company's proprietary elos® technology of optical energy and bi-polar radiofrequency to provide safe and efficacious treatments.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EMA backs orphan drug status for Vanda's imsidolimab in rare skin disease
- Adlai Nortye doses first patient in weekly arm of AN9025 trial
- Grifols starts two Phase 3 trials to expand immunoglobulin labels
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
